A new experimental contrast agent for magnetic resonance imaging could open a new approach to detecting lung cancer at a much earlier stage.

Researchers found that the protein-based agent, known as hProCA32.Collagen2, was able to identify lung tumors and metastatic lesions as small as 1 millimeter in animal studies. The findings were reported in Science Advances and highlighted by Reuters on September 16, 2026.

The technology is still experimental and has not yet been established as a routine diagnostic tool for people. However, researchers say the findings could eventually help doctors identify very small tumors and gather additional information about how cancer behaves.

How the New MRI Agent Works

The experimental contrast agent is designed to target type I collagen, a structural protein found at higher levels in aggressive tumors and metastatic lesions.

By focusing on changes in collagen around tumors, researchers hope the technology can provide more than simply an image showing where a tumor is located.

The MRI approach could potentially reveal changes associated with tumor aggressiveness and the way cancer may spread.

Detecting Smaller Tumors Could Matter

Lung cancer can be difficult to detect at an early stage, particularly when tumors are still very small.

The researchers reported that hProCA32.Collagen2 detected tumors and metastases measuring around 1 millimeter in animal experiments. Being able to identify smaller abnormalities could eventually give doctors more information when evaluating suspicious tissue.

However, results from animal studies cannot automatically be applied to human patients. Additional research and clinical testing would be needed before determining whether the technology is safe and effective for routine medical use.

A Potential Alternative to Some Invasive Procedures

Another area of interest is the possibility of obtaining more information from imaging without relying entirely on invasive procedures.

The research team said the technology could potentially reduce the need for some invasive biopsies by providing information about tumor characteristics through imaging. It may also help researchers monitor changes in tumor collagen over time.

That could become particularly relevant for personalized cancer care if future human studies confirm the findings.

No Radiation From MRI Imaging

MRI uses magnetic fields and radio waves rather than ionizing radiation.

The researchers highlighted that their experimental contrast agent could help visualize very small tumors and metastatic lesions without exposing patients to radiation from the imaging procedure itself.

Still, the contrast agent itself would need to undergo extensive evaluation before it could be considered for clinical use.

What Comes Next?

The latest findings represent an early stage of research rather than an available cancer screening method.

Future studies will need to determine whether the contrast agent performs similarly in humans, whether it has an acceptable safety profile, and whether it provides meaningful advantages over existing diagnostic methods.

If those questions can be answered through clinical research, the technology could eventually contribute to earlier and more detailed lung cancer detection.